Luminara Therapeutics

Illuminating the future of vision
Luminara Therapeutics is developing a new non-invasive approach to help preserve vision in Retinitis Pigmentosa.
We are building a broad, mutation-agnostic therapy candidate designed for the many patients still progressing toward vision loss without a practical treatment option.
Contact us

A biotech company focused on vision preservation
Luminara Therapeutics is a science-led biotech company developing innovative therapies for retinal degeneration.
Our mission is to preserve sight before it is irreversibly lost, starting with Retinitis Pigmentosa — a progressive retinal disease that affects millions of people worldwide.
We believe preserving sight means preserving independence, mobility and a life still fully open.
Science-led
Grounded in translational retinal research and a rigorous approach to drug development.
Patient-focused
Designed with real patients in mind — those who still have no practical treatment option.
Mission-driven
Committed to preserving natural vision before it is irreversibly lost.
Who we are
Luminara brings together the four capabilities that matter most in early biotech:
Scientific discovery I Translational peptide R&D I Disciplined execution I Scalable company building.
Enrique J. de la Rosa
Scientific Founder
Retinal neurodegeneration translational leadership
Catalina Hernández Sánchez
Co-Founder / Peptide Science
Peptide MoA and translational biology
Pilar Najarro
Partner & COO
Operational execution across science and business

Science-led. Execution-driven. Built for partnering.
Retinitis Pigmentosa still leaves most patients behind
Retinitis Pigmentosa gradually damages the photoreceptors of the retina. Patients often begin with night blindness and low-light impairment, followed by progressive loss of peripheral vision and, in many cases, severe visual impairment.
Despite scientific progress, most people living with RP still do not have a broadly accessible, non-invasive treatment option.
1
Progressive vision loss
RP causes ongoing, irreversible damage to retinal photoreceptors over time, often beginning in youth.
2
Limited treatment options
Only a narrow subset of patients with specific mutations currently have access to approved gene therapies.
1
High unmet need
The vast majority of patients worldwide have no practical treatment to slow or halt their vision loss.
2
Most patients underserved
Mutation-specific therapies, by definition, cannot reach the broad RP population in need of help.
Precision Peptides for Vision Preservation
P1614: a new therapeutic candidate for broad vision preservation
Luminara is developing P1614, a synthetic peptide-based therapy candidate designed to slow retinal degeneration. Unlike approaches focused on a single genetic mutation, P1614 is being developed as a broader, mutation-agnostic approach with topical eye-drop delivery.
Topical delivery
Designed for administration as an eye drop — non-invasive, simple and suited for chronic use in everyday life.
Mutation-agnostic approach
Developed to address retinal degeneration broadly, with the potential to benefit patients regardless of their specific genetic mutation.
Peptide-based candidate
Built on synthetic peptide biology, offering a differentiated mechanism with a strong translational rationale.
A non-invasive candidate designed for broad patient reach.
Peptide-based Synthetic peptide candidate with a clear translational path from bench to clinic.
Topical delivery Eye-drop administration designed for chronic use and real-world adoption.
Broad reach Mutation-agnostic design aimed at the wide population of underserved RP patients.
A different approach to an urgent need
Many current approaches in inherited retinal disease are highly specific, invasive or difficult to scale. Luminara is focused on a practical therapeutic path: broad eligibility, simple delivery and the potential to preserve natural vision.
Broad
Designed to reach beyond single-mutation therapies, with the potential to benefit a wide and diverse RP patient population.
Non-invasive
Built around topical eye-drop delivery — no injections, no surgery, no barriers to patient access.
Practical
Developed with chronic use and real-world adoption in mind, not just clinical elegance.
Scalable
Designed as a platform for broad patient impact — a therapy built to reach the many, not the few.

Partner-ready — built for collaboration with ophthalmology and retina leaders who share our commitment to vision preservation.
Rooted in translational retinal science
Luminara's work is based on scientific research in retinal neurodegeneration, peptide biology and vision preservation. The company builds on a strong academic and translational foundation, with a development vision focused on turning promising science into a clinically usable therapy candidate.
Science-led.
Grounded in rigorous research on retinal neurodegeneration and peptide-based neuroprotection.
Patient-focused.
Every development decision is made with the underserved RP patient population in mind.
Built for translation.
From academic insight to a clinically viable candidate — designed from the start to reach patients.
Built for collaboration.
Open to partnerships with researchers, ophthalmologists and institutions advancing retinal medicine.
Science-led. Patient-focused. Built for translation.
Luminara brings together expertise in retinal biology, peptide chemistry and translational medicine. Our approach is grounded in the belief that good science, rigorously developed, can become a practical therapy that reaches the patients who need it most.


Changing the story of Retinitis Pigmentosa
For too many patients, RP is still a story of progressive and irreversible vision loss. Luminara is working toward a future where treatment can begin earlier, reach more patients and help preserve vision before it disappears.
Today
Most RP patients have no broadly accessible, non-invasive treatment. P1614 is in active development to address this gap.
Near term
Advancing P1614 through preclinical and translational stages toward a clinically usable therapy candidate.
The goal
A non-invasive, mutation-agnostic therapy that can reach patients broadly and help preserve natural vision.
The future
A world where RP is no longer synonymous with inevitable vision loss — where sight, and the life it enables, can be preserved.
Because preserving sight means preserving a life still fully open.
Let's illuminate the future of vision together
Luminara Therapeutics is open to conversations with investors, strategic partners, researchers and collaborators who share our commitment to preserving vision.
Investors
We welcome conversations with investors who believe in the potential of science-led vision preservation.
Strategic partners
Open to collaboration with ophthalmology leaders, retina specialists and pharma organizations.
Researchers
Interested in connecting with academic and translational researchers in retinal medicine and peptide biology.

© 2026 Luminara Therapeutics SL
Contact:
Pilar Najarro
COO & Partner
pnajarro@luminaratherapeutics.com